Christopher M. Rembold

Christopher M. Rembold

Auto-generated profile, based on publicly available information

Christopher M. Rembold

Cardiovascular Division, Department of Internal Medicine

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2008 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
JSJames Stein
James Stein
CKClaudia E Korcarz
Claudia E Korcarz
RHR. Todd Hurst
R. Todd Hurst
ELEva Lonn
Eva Lonn
CKChristopher B. Kendall
Christopher B. Kendall
WPWendy S. Post
Wendy S. Post

22 August 2012 in JAMA
Verified
Journal Article
Open access
PDF file
HRHester M. Den Ruijter
Hester M. Den Ruijter
SISanne Peters, The George Institute
Sanne Peters, The George Institute
TATodd J. Anderson
Todd J. Anderson
ABAnnie R. Britton
Annie R. Britton
JDJacqueline M. Dekker
Jacqueline M. Dekker
MBMichiel L. Bots
Michiel L. Bots
Cardiovascular disease is among the leading causes of morbidity and mortality worldwide. Preventive treatment of high-risk asymptomatic individuals depends on accurate prediction of a person's risk to develop a cardiovascular event. Currently, cardiovascular risk prediction in asymptomatic individuals is based on the level of cardiovascular risk factors incorporated in scoring equations.1 Several scores are available, with the Framingham Risk Score among the most widely used.1,2 These risk equations perform reasonably well, yet there remains considerable overlap in estimated risk between those who are affected by a cardiovascular event and those who are not.3 Improvement in cardiovascular risk prediction is needed and may be established by including a measure of preclinical atherosclerosis in the risk prediction algorithms4 because atherosclerosis underlies the occurrence of cardiovascular events, develops over decades, and has a prolonged asymptomatic phase during which it is possible to modify the course of the disease.5

1 August 1998 in BMJ
Verified
Journal Article
Closed access
PDF file
CRChristopher M Rembold
Christopher M Rembold
Objectives : To develop the number needed to screen, a new statistic to overcome inappropriate national strategies for disease screening.Number needed to screen is defined as the number of people that need to be screened for a given duration to prevent one death or adverse event. Design : Number needed to screen was calculated from clinical trials that directly measured the effect of a screening strategy. From clinical trials that measured treatment benefit, the number needed to screen was estimated as the number needed to treat from the trial divided by the prevalence of heretofore unrecognised or untreated disease. Directly calculated values were then compared with estimate number needed to screen values. Subjects : Standard literature review. Results : For prevention of total mortality the most effective screening test was a lipid profile. The estimated number needed to screen for dyslipidaemia (low density lipoprotein cholesterol concentration >4.14 mmol/1) was 418 if detection was followed by pravastatin treatment for 5 years. This indicates that one death in 5 years could be prevented by screening 418 people. The estimated number needed to screen for hypertension was between 274 and 1307 for 5 years (for 10 mm Hg and 6 mm Hg diastolic blood pressure reduction respectively) if detection was followed by treatment based on a diuretic. Screening with haemoccult testing and mammography significantly decreased cancer specific, but not total, mortality. The number needed to screen for haemoccult screening to prevent a death from colon cancer was 1374 for 5 years, and the number needed to screen for mammography to prevent a death from breast cancer was 2451 for 5 years for women aged 50-59. Conclusion : These data allow the clinician to prioritise screening strategies. Of the screening strategies evaluated, screening for, and treatment of, dyslipidaemia and hypertension seem to produce the largest clinical benefit.

1 March 1990 in The American Journal of Cardiology
Verified
Journal Article
Closed access
HGHoward P. Gutgesell
Howard P. Gutgesell
CRChristopher M. Rembold
Christopher M. Rembold

2 July 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CGCrystel M. Gijsberts
Crystel M. Gijsberts
KGKarlijn A. Groenewegen
Karlijn A. Groenewegen
IHImo E. Hoefer
Imo E. Hoefer
MEMarinus J. C. Eijkemans
Marinus J. C. Eijkemans
FAFolkert W. Asselbergs
Folkert W. Asselbergs
HRHester M. Den Ruijter
Hester M. Den Ruijter
Clinical manifestations and outcomes of atherosclerotic disease differ between ethnic groups. In addition, the prevalence of risk factors is substantially different. Primary prevention programs are based on data derived from almost exclusively White people. We investigated how race/ethnic differences modify the associations of established risk factors with atherosclerosis and cardiovascular events. We used data from an ongoing individual participant meta-analysis involving 17 population-based cohorts worldwide. We selected 60,211 participants without cardiovascular disease at baseline with available data on ethnicity (White, Black, Asian or Hispanic). We generated a multivariable linear regression model containing risk factors and ethnicity predicting mean common carotid intima-media thickness (CIMT) and a multivariable Cox regression model predicting myocardial infarction or stroke. For each risk factor we assessed how the association with the preclinical and clinical measures of cardiovascular atherosclerotic disease was affected by ethnicity. Ethnicity appeared to significantly modify the associations between risk factors and CIMT and cardiovascular events. The association between age and CIMT was weaker in Blacks and Hispanics. Systolic blood pressure associated more strongly with CIMT in Asians. HDL cholesterol and smoking associated less with CIMT in Blacks. Furthermore, the association of age and total cholesterol levels with the occurrence of cardiovascular events differed between Blacks and Whites. The magnitude of associations between risk factors and the presence of atherosclerotic disease differs between race/ethnic groups. These subtle, yet significant differences provide insight in the etiology of cardiovascular disease among race/ethnic groups. These insights aid the race/ethnic-specific implementation of primary prevention.

1 September 1988 in Circulation Research
Verified
Journal Article
Closed access
CRC M Rembold
C M Rembold
RMR A Murphy
R A Murphy
Our objective was to test the hypotheses that 1) myoplasmic [Ca2+] is the primary determinant of crossbridge phosphorylation and that 2) phosphorylation is the primary determinant of crossbridge interactions with the thin filament in swine carotid arterial smooth muscle. We tested these hypotheses by evaluating the relation between aequorin-estimated myoplasmic [Ca2+], myosin light chain phosphorylation, shortening velocity at zero load (V0), and stress at various times after stimulation with histamine, phenylephrine, and depolarization with KCl. Agonist-induced changes in myoplasmic [Ca2+] were associated with predictable changes in myosin phosphorylation. Depolarization required proportionally higher changes in myoplasmic [Ca2+] for a given change in myosin phosphorylation. The relation between phosphorylation and V0 or steady-state stress was invariant with all tested stimuli. This suggests that Ca2+-dependent crossbridge phosphorylation is the primary determinant of the mechanical response.